Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.61 |
| ▸ | HTR2C | P28335 | 8/20 | 0.59 |
| ▸ | QDPR | P09417 | 3/20 | 0.52 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.49 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28688462 | 0.82 | SIGMAR1 (0.69) | SIGMAR1HTR2CQDPR | |
| SCHEMBL3385014 | 0.81 | SIGMAR1 (0.68) | SIGMAR1HTR2CQDPRFTOINPPL1 | |
| Hydrochloric Acid SCHEMBL28678896 | 0.81 | HTR2C (0.70) | SIGMAR1HTR2CQDPRFTO | |
| Hydrochloric Acid SCHEMBL2158640 | 0.80 | HTR2C (0.69) | SIGMAR1HTR2CQDPRFTOINPPL1 | |
| SCHEMBL2269930 | 0.78 | SIGMAR1 (0.67) | SIGMAR1HTR2CQDPRFTOINPPL1 | |
| SCHEMBL19459063 | 0.78 | HTR2C (0.62) | SIGMAR1HTR2CQDPRFTOINPPL1 | |
| Hydrochloric Acid SCHEMBL16423171 | 0.76 | HTR2C (0.68) | SIGMAR1HTR2CQDPRFTOINPPL1 | |
| SCHEMBL531984 | 0.76 | SIGMAR1 (1.00) | SIGMAR1HTR2CQDPRINPPL1 | |
| SCHEMBL3386020 | 0.76 | SIGMAR1 (0.59) | SIGMAR1HTR2CQDPR | |
| SCHEMBL3385639 | 0.75 | HTR2C (0.59) | SIGMAR1HTR2CQDPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102532162-B | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2015-05-27 | — | — | CN | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | SIGMAR1 234/4885HTR2C 2910/4885QDPR 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.